Advertisement
Advertisement
U.S. Markets close in 6 hrs 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.22000.0000 (0.00%)
As of 09:34AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2200
Open1.2800
Bid1.2000 x 3000
Ask0.0000 x 1800
Day's Range1.2000 - 1.2400
52 Week Range1.1500 - 3.1800
Volume57,501
Avg. Volume1,263,208
Market Cap92.995M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-10.3330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
  • GlobeNewswire

    Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH

    EDISON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the Company’s lead drug candidate, CRV431, for the treatment of NASH. The FDA Fast Track design

  • GlobeNewswire

    Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

    EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. Additionally, CRV431 was as effectiv

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021

    EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AAS

Advertisement
Advertisement